SR One Capital Management LP acquired a new stake in enGene Holdings Inc. (NASDAQ:ENGN – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 500,000 shares of the company’s stock, valued at approximately $4,715,000. enGene accounts for 1.5% of SR One Capital Management LP’s holdings, making the stock its 8th biggest holding. SR One Capital Management LP owned 1.13% of enGene as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also made changes to their positions in the company. Altitude Crest Partners Inc. purchased a new position in enGene in the first quarter worth approximately $2,039,000. Omega Fund Management LLC acquired a new position in shares of enGene during the fourth quarter worth $10,441,000. Janus Henderson Group PLC purchased a new position in enGene in the first quarter valued at $17,095,000. Finally, BVF Inc. IL acquired a new stake in enGene in the fourth quarter valued at $20,777,000. 64.16% of the stock is owned by institutional investors and hedge funds.
enGene Stock Up 0.7 %
enGene stock opened at $7.21 on Friday. The stock has a 50-day simple moving average of $7.30 and a 200-day simple moving average of $11.17. The company has a market capitalization of $318.44 million, a P/E ratio of -4.34 and a beta of -0.67. The company has a debt-to-equity ratio of 0.09, a quick ratio of 42.80 and a current ratio of 19.52. enGene Holdings Inc. has a fifty-two week low of $4.94 and a fifty-two week high of $43.00.
Wall Street Analysts Forecast Growth
ENGN has been the topic of a number of recent analyst reports. Morgan Stanley reiterated an “overweight” rating and issued a $40.00 price objective on shares of enGene in a report on Wednesday, September 11th. Oppenheimer initiated coverage on shares of enGene in a report on Wednesday, August 28th. They set an “outperform” rating and a $30.00 price objective on the stock. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, enGene presently has a consensus rating of “Buy” and a consensus price target of $33.67.
Read Our Latest Report on ENGN
enGene Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Read More
- Five stocks we like better than enGene
- How to Calculate Return on Investment (ROI)
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- MarketBeat Week in Review – 9/16 – 9/20
- Bank Stocks – Best Bank Stocks to Invest In
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.